Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1999-06-14
2001-11-06
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S233200, C514S253030, C546S121000, C544S127000, C544S362000
Reexamination Certificate
active
06313136
ABSTRACT:
TECHNICAL FIELD
The present invention relates to novel compounds, and pharmaceutically acceptable salts thereof, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above. The invention also relates to new intermediates for in the preparation of the novel compounds.
BACKGROUND ART
Substituted imidazo[1,2-a]pyridines, useful in the treatment of peptic ulcer diseases, are known in the art, e.g. from EP-B-0033094 and U.S. Pat. No. 4,450,164 (Schering Corporation); from EP-B-0204285 and U.S. Pat. No. 4,725,601 (Fujisawa Pharmaceutical Co.); and from publications by J. J. Kaminski et al. in the Journal of Medical Chemistry (vol. 28, 876-892, 1985; vol. 30, 2031-2046, 1987; vol. 30, 2047-2051, 1987; vol. 32, 1686-1700, 1989; and vol. 34, 533-541, 1991).
For a review of the pharmacology of the gastric acid pump (the H
+
, K
+
-ATPase), see Sachs et al. (1995) Annu. Rev. Pharmacol. Toxicol. 35: 277-305.
DISCLOSURE OF THE INVENTION
It has surprisingly been found that compounds of the Formula I, which are imidazo pyridine derivatives in which the phenyl moiety is substituted, and in which the imidazo pyridine moiety is substituted with a carboxamide group in 6-position are particularly effective as inhibitors of the gastrointestinal H
+
, K
+
-ATPase and thereby as inhibitors of gastric acid secretion. The carboxamide group in 6-position is optionally selected to give compounds of Formula I a molecular weight≦600.
In one aspect, the invention thus relates to compounds of the general Formula I
or a pharmaceutically acceptable salt thereof, wherein
R
1
is
(a) H,
(b) CH
3
, or
(c) CH
2
OH;
R
2
is
(a) CH
3
, or
(b) CH
2
CH
3
;
R
3
is
(a) H,
(b) C
1
-C
6
alkyl,
(c) hydroxylated C
1
-C
6
alkyl, or
(d) halogen;
R
4
is
(a) H,
(b) C
1
-C
6
alkyl,
(c) hydroxylated C
1
-C
6
alkyl, or
(d) halogen;
R
5
is
(a) H, or
(b) halogen;
R
6
and R
7
are independently selected substituents, comprising C, H, N, O, S, Se, P and Halogen atoms, which give compounds of Formula I a molecular weight≦600, provided that at least one of R
6
and R
7
can not be H, C
1
-C
6
alkyl, hydroxylated C
1
-C
6
alkyl, or C
1
-C
6
alkoxy-substituted C
1
-C
6
alkyl, and
X is
(a) NH, or
(b) O.
As used herein, the term “C
1
-C
6
alkyl” denotes a straight or branched alkyl group having from 1 to 6 carbon atoms. Examples of said C
1
-C
6
alkyl include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl and straight- and branched-chain pentyl and hexyl.
The term “halogen” includes fluoro, chloro, bromo and iodo.
The substitutents R
6
and R
7
are defined as independently selected substituents, comprising C, H, N, O, S, Se, P or Halogen atoms, which give compounds of Formula I a molecular weight≦600, which is a definition easily understood by a person skilled in the art.
Examples of substituents that fall within the scope of this definition includes, but is not limited to,
(a) H,
(b) C
1
-C
6
alkyl,
(c) hydroxylated C
1
-C
6
alkyl,
(d) C
1
-C
6
alkoxy-substituted C
1
-C
6
alkyl,
(e) C
2
-C
6
alkenyl,
(f) C
2
-C
6
alkynyl,
(g) halogenated C
1
-C
6
alkyl,
(h) C
3
-C
8
cycloalkyl,
(i) cycloalkyl-substituted C
1
-C
6
alkyl,
(j) aryl, in which aryl represents phenyl, pyridyl, thienyl, imidazolyl, indolyl, naphthyl or furanyl, optionally substituted by one or more substituents selected from halogen, C
1
-C
6
alkyl, C
1
-C
6
alkoxy, CF
3
, OH, nitro, amino, C
1
-C
6
alkyl-NH—, (C
1
-C
6
alkyl)
2
—N—, or CN or NH
2
SO
2
,
(k) aryl substituted C
1
-C
6
alkyl, in which aryl represents phenyl, pyridyl, thienyl, imidazolyl, indolyl, naphthyl or furanyl, optionally substituted with one or more substituents selected from halogen, C
1
-C
6
alkyl, C
1
-C
6
alkoxy, CF
3
, OH, nitro, amino C
1
-C
6
alkyl-NH—, (C
1
-C
6
alkyl)
2
—N—, CN or NH
2
SO
2
,
(1) R
8
—(C
1
-C
6
) alkyl-, wherein R
8
is NH
2
C═O—, C
1
-C
6
alkyl-NHC═O—, (C
1
-C
6
alkyl)
2
NC═O—, C
1
-C
6
alkyl-OOC—, NH
2
SO
2
—, C
1
-C
6
alkyl-SO
2
NH—, ArSO
2
NH—, cyano, C
1
-C
6
alkyl-CO—NH—, C
1
-C
6
alkyl-OOCNH—, C
1
-C
6
alkyl-O—, C
7
-C
12
alkyl-O—C
1
-C
6
alkyl-SO—, C
1
-C
6
alkyl-S—, C
1
-C
6
alkyl-SO
2
—, C
1
-C
6
alkyl-C═O—, NH
2
—, C
1
-C
6
alkyl-NH—, (C
1
-C
6
alkyl)
2
N—, ArCONH—, Ar(C
1
-C
6
alkyl)CONH, ArNHSO
2
—, (Ar)
2
—N—SO
2
—, C
1
-C
6
alkyl-NHSO
2
—, ArS—, ArSO—, ArSO
2
—, ArC═O—, NH
2
CONH—C
1
-C
6
alkyl-NHCONH—, (C
1
-C
6
alkyl)
2
—NCONH—, ArNHCONH—, Ar—O—, Ar—NH—, Ar(C
1
-C
6
alkyl)N—, (C
1
-C
6
alkyl)
2
NSO
2
—, hydroxylated C1-C6 alkyl-O— or morpholinyl; wherein Ar represents phenyl, pyridyl, thienyl, imidazolyl, indolyl, naphthyl or furanyl, optionally substituted with one or more substituents selected from halogen, C
1
-C
6
alkyl, C
1
-C
6
alkoxy, CF
3
, OH, CN, nitro, amino, C
1
-C
6
alkyl-NH—, or (C
1
-C
6
alkyl)
2
N—,
(m) C
7
-C
12
,
(n) OH, O—C
1
-C
6
alkyl, or O-hydroxylated C
1
-C
6
alkyl,
o)
wherein R
9
and R
10
are independently H or C
1
-C
6
alkyl,
p) R
11
—(C
1
-C
6
) alkyl-COO—(C
1
-C
6
) alkyl- wherein R
11
is HOOC—, C
1
-C
6
alkyl-OOC— or an amino carbonyl group with the formula
wherein R
12
, R
13
are the same or different H, or C
1
-C
6
alkyl
R
6
and R
7
, together with the nitrogen atom to which they are attached, form a saturated or unsaturated ring optionally containing one or more further heteroatoms (for example morpholine, piperazine, pyrrolidine, piperidine), optionally substituted with one or more substituents selected from halogen, C
1
-C
6
alkyl, C
1
-C
6
alkoxy, CF
3
, OH, nitro, amino C
1
-C
6
alkyl-NH—, (C
1
-C
6
alkyl)
2
—N—, CN, NH
2
SO
2
, phenyl, NH
2
CO—, C
1
-C
6
alkyl-CO—, the ring can be fused with an aromatic ring (such as tetrahydroquinoline);
Both the pure enantiomers, racemic mixtures and unequal mixtures of two enantiomers are within the scope of the invention. It should be understood that all the diastereomeric forms possible (pure enantiomers, racemic mixtures and unequal mixtures of two enantiomers) are within the scope of the invention. Also included in the invention are derivatives of the compounds of the Formula I which have the biological function of the compounds of the Formula I, such as prodrugs.
It will also be appreciated by those skilled in the art, although derivatives of compounds of formula I may not possess pharmacological activity as such, they may be administered parenterally or orally and thereafter metabolised in the body to form compounds of the invention which are pharmacologically active. Such derivatives may therefore be described as “prodrugs”. All prodrugs of compounds of formula I are included within the scope of the invention.
Depending on the process conditions the end products of the Formula I are obtained either in neutral or salt form. Both the free base and the salts of these end products are within the scope of the invention.
Acid addition salts of the new compounds may in a manner known per se be transformed into the free base using basic agents such as alkali or by ion exchange. The free base obtained may also form salts with organic or inorganic acids.
In the preparation of acid addition salts, preferably such acids are used which form suitably pharmaceutically acceptable salts. Examples of such acids are hydrohalogen acids such as hydrochloric acid, sulphuric acid, phosphoric acid, nitric acid, aliphatic, alicyclic, aromatic or heterocyclic carboxyl or sulphonic acids, such as formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid,
Amin Kosrat
Dahlström Mikael
Nordberg Peter
Starke Ingemar
Astrazeneca AB
Dentz Bernard
White & Case LLP
LandOfFree
Imidazo pyridine derivatives which inhibit gastric acid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazo pyridine derivatives which inhibit gastric acid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazo pyridine derivatives which inhibit gastric acid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2602487